Physician profile
Robert C Harizi
NPI 1093776957
$6,054.90
in general payments reported to CMS, 2019-2025
26 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,094 · 2020: $902 · 2021: $812 · 2022: $855 · 2023: $379 · 2024: $711 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $697.52 | 2019-2025 | |
| Abiomed | $648.90 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $550.24 | 2019-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.29 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $504.09 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $486.60 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $413.02 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $390.56 | 2019-2022 | |
| Amgen INC. | $354.11 | 2019-2024 | Repatha |
| Bardy Diagnostics, INC. | $275.00 | 2020 | |
| Lantheus Medical Imaging, INC. | $212.09 | 2019-2024 | |
| Medtronic Vascular, INC. | $145.82 | 2019-2020 | |
| Vifor Pharma, INC. | $130.95 | 2019 | |
| Amarin Pharma, INC. | $126.10 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $100.74 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $95.20 | 2019-2025 | Accolade Sr |
| Regeneron Healthcare Solutions, INC. | $88.34 | 2019-2020 | |
| Medtronic, INC. | $86.92 | 2021-2022 | |
| Abbott Laboratories | $42.86 | 2021-2025 | Amplatzer Amulet |
| Scpharmaceuticals INC. | $42.13 | 2024-2025 | |
| Z-Medica, LLC | $37.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.39 | 2021 | |
| Ge Healthcare | $20.41 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.25 | 2019 | |
| Chiesi USA, INC. | $18.95 | 2021 | |
| Astellas Pharma US INC | $15.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harizi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.